Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12816
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJohnston, Colin Ien
dc.date.accessioned2015-05-16T02:33:38Z
dc.date.available2015-05-16T02:33:38Z
dc.date.issued1989-05-16en
dc.identifier.citationClinical and Experimental Hypertension. Part A, Theory and Practice; 11(5-6): 1097-115en
dc.identifier.govdoc2676252en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12816en
dc.description.abstractThere are now numerous angiotensin converting enzyme (ACE) inhibitors under development, clinical trial or in clinical use for cardiovascular disease, a situation analagous to the beta blockers. They currently vary in their chemical and physical structure, whether they contain a sulphydril group or are pro-drugs, and in their pharmacokinetics. Whether these differences will convey any special or particular clinical advantages to individual ACE inhibitors has yet to be established. Further research is necessary to determine whether tissue ACEs are merely isoenzymes or whether they differ in their functional properties. Different bioavailability in tissues of the individual ACE inhibitors could confer differing pharmacodynamic properties. ACE inhibitors have been a major advance in the treatment of hypertension and heart failure. In heart failure they have been shown to improve the haemodynamics, to improve symptoms, and most recently, to prolong survival. In hypertension, ACE inhibitors have some physiological advantages over current antihypertensive agents. They have several favourable cardiovascular effects without metabolic disadvantages which provide a theoretical basis for cardio-protection in hypertensive patients.en
dc.language.isoenen
dc.subject.otherAngiotensin-Converting Enzyme Inhibitors.adverse effects.therapeutic useen
dc.subject.otherAnimalsen
dc.subject.otherClinical Trials as Topicen
dc.subject.otherHeart Diseases.prevention & controlen
dc.subject.otherHumansen
dc.subject.otherHypertension.drug therapyen
dc.subject.otherKidney Diseases.prevention & controlen
dc.titleAngiotensin converting enzyme inhibitors: differences and advantages for first line therapy in hypertension.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical and experimental hypertension. Part A, Theory and practiceen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages1097-115en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/2676252en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.